ECT in a patient with Parkinson's disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET

Journal of Neural Transmission

Volumn 118, Issue 4, 2011, Pages 647-650

  Fernández Corcuera, Paloma ^a   Aguilar, Salvatore ^a   Viçens, Víctor ^a   Mora, Jaume ^b   Benitez, Ana ^b   García Burillo, Amparo ^d   Pomarol Clotet, Edith ^c   McKenna, Peter ^c  

^a Aguts Unit   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Benito Menni Complex Assistencial en Salut Mental   (Spain)

^d Hospital Delfos   (Spain)

Author keywords

123I Ioflupane; Dopamine; Electroconvulsive therapy; Parkinson's disease; Schizophrenia; Single photon emission tomography

Indexed keywords

BIPERIDEN; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOPAMINE TRANSPORTER; HALOPERIDOL; IOFLUPANE I 123; LORAZEPAM; OLANZAPINE; PIPOTIAZINE; QUETIAPINE;

ADULT; ARTICLE; BEHAVIOR; CASE REPORT; CAUDATE NUCLEUS; DELUSION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MENTAL HEALTH; PARKINSON DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CAUDATE NUCLEUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTROSHOCK; FEMALE; HUMANS; MIDDLE AGED; NORTROPANES; PARKINSON DISEASE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79956210518     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0615-8     Document Type: Article

References (22)

1. Andersen K, Balldin J, Gottfries CG, Granérus AK, Modigh K, Svennerholm L, Wallin A (1987) A double-blind evaluation of electroconvulsive therapy in Parkinson disease with "on-off" phenomena. Acta Neurol Scand 76(3):191-199
2. Bruins Slot LA, Palmier C, Tardif S, Cussac D (2007) Actions of novel antipsychotics at human D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology 53(2):232-241 (Pubitemid 47187452)
3. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Murherjee J (2006) D2/D3 dopamine receptor binding with (F-18) fallypride in thalamus and cortex patients with schizophrenia. Schizophr Res 85(1-3):232-244 (Pubitemid 43947535)
4. Fahn S, Elton R (1987) Members of the updrs Development Committee Recent Developments in Parkinson's Disease. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). Macmillan Health Care Information, vol 2, pp 153-163, 293-304. Florham Park
5. Fall PA, Ekman R, Granérus AK, Thorell LH, Wålinder J (1995) ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect 10(2-3):129-140 (Pubitemid 26014880)
6. Fall PA, Ekberg S, Granérus AK, Granérus G (2000) ECT in Parkinson's disease-dopamine transporter visualised by 123I-BCIT SPECT. J Neural Transm 107:997-1008
7. Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427-442
8. Krystal AD, Coffey CE (1997) Neuropsychiatric considerations in the use of electroconvulsive therapy. J Neuropsychiatry Clin Neurosci 9(2):283-292 (Pubitemid 27198808)
9. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O et al (2000) Striatal dopamine transporter binding in neuroleptic naive patients with schizophrenia studied with PET. Am J Psychiatry 157:269-271 (Pubitemid 30080910)
10. Lahti AC, Weiler M, Carlsson A, Tamminga CA (1998) Effects of the D3 and auto receptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105(6-7):719-734 (Pubitemid 28454522)
11. Lammers CH, Diaz J, Schwartz JC, Sokoloff P (2000) Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5(4):378-388 (Pubitemid 30455951)
12. Landau AM, Chakravarty MM, Clark CM, Zis AP, Doudet DJ (2010) Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 13:1-8
13. Lorenzo i Bosquet C, Cuberas Borros G, Miquel Rodriguez F, Caresia P, Aguade Bruix S, Castell Conesa J (2005) Quantitative evaluation of 123I-FP-CIT SPECT: validation of a semiautomated method. Rev Esp Med Nucl 24(4):244-249
14. Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernández-Egea E, Pavia J, Prats A, Pons F, Bernardo M (2007) Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggest an illness trait. Psychopharmacology (Berl) 191(3):805-811 (Pubitemid 46355894)
15. Mehler-Wex C, Riederer P, Gerlach M (2006) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 3-4:167-179
16. Ortega Lozano SJ, Martínez del Valle Torres MD, Jiménez-Hoyuela García JM, Gutierrez Cardo AL, Campos Arillo V (2007) Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism. Rev Esp Med Nucl 26(5):277-285 (Pubitemid 47572727)
17. Rizos EN, Chatziioannou S, Douzenis A, Siafakas N, Katsantoni E, Nikolaidou P, Papathanasiou M, Lykouras L (2010a) Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Eur Neuropsychopharmacol 20(2):132-136
18. Rizos EN, Chatziioannou S, Siafakas N, Douzenis A, Katsantoni E, Mandrapilia A, Bacalis S, Fotiadis C, Lykouras L (2010b) Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia-a case report. Prog Neuropsychopharmacol Biol Psychiatry 34(6):1135-1136
19. Strome EM, Zis AP, Doudet DJ (2007) Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6 - OHDA-lesioned rats. J Psychiatry Neurosci 32(3):193-202 (Pubitemid 46903860)
20. Tolosa E, Borght TV, Moreno E (2007) DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 22(16):2346-2351
21. Vogel M, Pfeifer S, Schaub RT, Grabe HJ, Barnow S, Freyberger HJ, Cascorbi I (2004) Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50(4):305-310 (Pubitemid 39482670)
22. Vogel M, Busse S, Freyberger HJ, Grabe HJ (2006) Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis. Med Hipotheses 67(2):354-358 (Pubitemid 43825612)